HC Wainwright Weighs in on Verona Pharma Q1 Earnings

Verona Pharma plc (NASDAQ:VRNA) – HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Verona Pharma in a research report issued on Friday, February 28th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings of $0.16 per share for the quarter. HC Wainwright has a “Buy” rating and a $75.00 price objective on the stock. The consensus estimate for Verona Pharma’s current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Verona Pharma’s Q2 2026 earnings at $0.40 EPS.

Several other brokerages have also issued reports on VRNA. Roth Mkm began coverage on Verona Pharma in a research note on Friday, January 10th. They set a “buy” rating and a $68.00 price target for the company. Truist Financial reiterated a “buy” rating and issued a $57.00 price objective (up previously from $44.00) on shares of Verona Pharma in a report on Wednesday, January 8th. Canaccord Genuity Group lifted their price objective on Verona Pharma from $44.00 to $72.00 and gave the stock a “buy” rating in a report on Wednesday, February 12th. Wells Fargo & Company lifted their price objective on Verona Pharma from $74.00 to $93.00 and gave the stock an “overweight” rating in a report on Friday, February 28th. Finally, Roth Capital upgraded Verona Pharma to a “strong-buy” rating in a report on Friday, January 10th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Verona Pharma currently has an average rating of “Buy” and an average target price of $66.83.

Verona Pharma Trading Up 2.3 %

Shares of VRNA stock opened at $67.50 on Monday. The company has a quick ratio of 12.88, a current ratio of 13.03 and a debt-to-equity ratio of 0.93. The business has a 50-day moving average price of $55.91 and a two-hundred day moving average price of $41.73. Verona Pharma has a 12-month low of $11.39 and a 12-month high of $70.40. The firm has a market cap of $5.43 billion, a P/E ratio of -35.16 and a beta of 0.41.

Insider Activity at Verona Pharma

In related news, CFO Mark W. Hahn sold 183,728 shares of the business’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $5.01, for a total transaction of $920,477.28. Following the transaction, the chief financial officer now owns 13,293,736 shares in the company, valued at $66,601,617.36. The trade was a 1.36 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO David Zaccardelli sold 162,800 shares of the business’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $5.01, for a total value of $815,628.00. Following the transaction, the chief executive officer now owns 14,204,752 shares in the company, valued at approximately $71,165,807.52. This represents a 1.13 % decrease in their position. The disclosure for this sale can be found here. 4.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Vermillion Wealth Management Inc. purchased a new position in Verona Pharma during the 4th quarter valued at about $46,000. GF Fund Management CO. LTD. purchased a new position in shares of Verona Pharma during the 4th quarter worth approximately $72,000. Castleark Management LLC purchased a new position in shares of Verona Pharma during the 4th quarter worth approximately $8,631,000. Woodline Partners LP grew its holdings in shares of Verona Pharma by 1.7% during the 4th quarter. Woodline Partners LP now owns 516,605 shares of the company’s stock worth $23,991,000 after acquiring an additional 8,660 shares during the period. Finally, Velan Capital Investment Management LP purchased a new position in shares of Verona Pharma during the 4th quarter worth approximately $2,322,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.